Cargando…

Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study

OBJECTIVE: The role of micronised progesterone in hormone regimens for transgender individuals undergoing feminising hormone therapy remains uncertain. We aimed to determine the effect of oral micronised progesterone on sleep quality, psychological distress, and breast development in transgender ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Brendan J, Frydman, Aviva S, Leemaqz, Shalem Y, Carroll, Meg, Grossmann, Mathis, Zajac, Jeffrey D, Cheung, Ada S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175584/
https://www.ncbi.nlm.nih.gov/pubmed/35521814
http://dx.doi.org/10.1530/EC-22-0170
_version_ 1784722483775012864
author Nolan, Brendan J
Frydman, Aviva S
Leemaqz, Shalem Y
Carroll, Meg
Grossmann, Mathis
Zajac, Jeffrey D
Cheung, Ada S
author_facet Nolan, Brendan J
Frydman, Aviva S
Leemaqz, Shalem Y
Carroll, Meg
Grossmann, Mathis
Zajac, Jeffrey D
Cheung, Ada S
author_sort Nolan, Brendan J
collection PubMed
description OBJECTIVE: The role of micronised progesterone in hormone regimens for transgender individuals undergoing feminising hormone therapy remains uncertain. We aimed to determine the effect of oral micronised progesterone on sleep quality, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy. DESIGN: Prospective case–control study. Twenty-three transgender individuals on stable oestradiol treatment newly commencing 100 mg oral progesterone (n = 23) and controls continuing standard care (n = 19) were assessed over 3 months. METHODS: Pittsburgh Sleep Quality Index (PSQI), Kessler psychological distress scale (K10), and Tanner stage to assess breast development were assessed at 0 and 3 months. Non-parametric analysis of covariance was used to compare differences between groups. RESULTS: Compared with controls over 3 months, there was no difference in PSQI (P = 0.35), K10 (P = 0.64), or Tanner stage (P = 0.42). There was no significant difference in the proportion of individuals with clinically significant improvement in PSQI (25% vs 22%, P = 0.84). One individual had a significant deterioration in psychological distress that improved following the cessation of progesterone. CONCLUSIONS: Low-dose progesterone was not associated with changes in sleep quality, psychological distress, or breast development over 3 months follow-up, though there was significant inter-individual variability. Larger, placebo-controlled trials are required to further evaluate different doses of progesterone in feminising hormone therapy regimens.
format Online
Article
Text
id pubmed-9175584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-91755842022-06-14 Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study Nolan, Brendan J Frydman, Aviva S Leemaqz, Shalem Y Carroll, Meg Grossmann, Mathis Zajac, Jeffrey D Cheung, Ada S Endocr Connect Research OBJECTIVE: The role of micronised progesterone in hormone regimens for transgender individuals undergoing feminising hormone therapy remains uncertain. We aimed to determine the effect of oral micronised progesterone on sleep quality, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy. DESIGN: Prospective case–control study. Twenty-three transgender individuals on stable oestradiol treatment newly commencing 100 mg oral progesterone (n = 23) and controls continuing standard care (n = 19) were assessed over 3 months. METHODS: Pittsburgh Sleep Quality Index (PSQI), Kessler psychological distress scale (K10), and Tanner stage to assess breast development were assessed at 0 and 3 months. Non-parametric analysis of covariance was used to compare differences between groups. RESULTS: Compared with controls over 3 months, there was no difference in PSQI (P = 0.35), K10 (P = 0.64), or Tanner stage (P = 0.42). There was no significant difference in the proportion of individuals with clinically significant improvement in PSQI (25% vs 22%, P = 0.84). One individual had a significant deterioration in psychological distress that improved following the cessation of progesterone. CONCLUSIONS: Low-dose progesterone was not associated with changes in sleep quality, psychological distress, or breast development over 3 months follow-up, though there was significant inter-individual variability. Larger, placebo-controlled trials are required to further evaluate different doses of progesterone in feminising hormone therapy regimens. Bioscientifica Ltd 2022-04-06 /pmc/articles/PMC9175584/ /pubmed/35521814 http://dx.doi.org/10.1530/EC-22-0170 Text en © The authors https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Research
Nolan, Brendan J
Frydman, Aviva S
Leemaqz, Shalem Y
Carroll, Meg
Grossmann, Mathis
Zajac, Jeffrey D
Cheung, Ada S
Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title_full Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title_fullStr Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title_full_unstemmed Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title_short Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
title_sort effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175584/
https://www.ncbi.nlm.nih.gov/pubmed/35521814
http://dx.doi.org/10.1530/EC-22-0170
work_keys_str_mv AT nolanbrendanj effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT frydmanavivas effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT leemaqzshalemy effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT carrollmeg effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT grossmannmathis effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT zajacjeffreyd effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy
AT cheungadas effectsoflowdoseoralmicronisedprogesteroneonsleeppsychologicaldistressandbreastdevelopmentintransgenderindividualsundergoingfeminisinghormonetherapyaprospectivecontrolledstudy